Riskpilot← Back to searchSign inGet full accessGlactone Pharma Development AB
ABActiveOrg 5569121121Kungsportsavenyen 22Research and experimental development on natural sciences and engineering · NACE 7210Est. 20120 employees
Revenue 2024
SEK 80K
0% vs 2023
EBITDA margin
35.0%
-28% vs 2023
Equity ratio
47.1%
Financial strength
Net profit 2024
SEK -3K
-127% vs 2023
| Revenue | SEK 80K | +0% |
| EBITDA | SEK 28K | -28% |
| Net profit | SEK -3K | -127% |
| Total assets | SEK 446K | -9% |
| Equity | SEK 210K | -2% |
| Employees | 0 | — |
Legal name
Glactone Pharma Development AB
Org number
5569121121
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
29 november 2012
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva forskning, utveckling, utbildning, marknadsföring och försäljning inom det medicinska området samt idka därmed förnelig verksamhet.
Address
Kungsportsavenyen 22
Phone
+46706649477
Email
gj@forsalven.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 80 | 80 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −868 | −757 | −4 945 | −3 575 | −3 429 | −808 | −238 | −18 | 39 | 28 |
| Depreciation & amort. | −0 | −0 | −13 444 | −68 | −1 083 | −2 | −17 | −19 | −28 | −31 |
| EBIT | −868 | −757 | −18 389 | −3 643 | −4 512 | −810 | −255 | −37 | 11 | −3 |
| Net financials | −114 | −150 | −185 | −20 | −6 | — | — | — | — | — |
| Profit before tax | −982 | −906 | −18 574 | −3 663 | −4 517 | −810 | −255 | −37 | 11 | −3 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −982 | −906 | −18 574 | −3 663 | −4 517 | −810 | −255 | −37 | 11 | −3 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11 389 | 16 457 | 2 383 | 3 715 | 483 | 669 | 497 | 533 | 490 | 446 |
| Equity | 1 884 | 2 478 | 908 | 2 552 | 229 | 494 | 239 | 203 | 214 | 210 |
| Long-term debt | 9 168 | 13 567 | 449 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 337 | 412 | 1 026 | 1 163 | 255 | 174 | 257 | 330 | 277 | 236 |
| Total debt | 9 505 | 13 979 | 1 475 | 1 163 | 255 | 174 | 257 | 330 | 277 | 236 |
EBITDA margin
35.0%
This company
15.8%
Market median
+122% vs market
20152024
Equity ratio
47.1%
This company
38.2%
Market median
+23% vs market
20152024
Return on equity
-1.4%
This company
18.4%
Market median
-108% vs market
20152024
Net profit margin
-3.8%
This company
8.1%
Market median
-147% vs market
20152024
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20152024
Debt / equity
1.12×
This company
0.62×
Market median
-81% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AH Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Glactone Pharma AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Glactone Pharma AB
Glactone Pharma Development AB Board members of Glactone Pharma Development AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andreas Henrik Alexander Brodström | Chief Auditor | 0 companies |
| Anders Sigvard Bjartell | Board of Directors | 0 companies |
| Daniel Martin Lifveredson | Board of Directors | 0 companies |
| Karin Rebecka Hellsten | Board of Directors | 0 companies |
| Jan Birger Fredrik Törnell | Chairman | 0 companies |